A Guide to Primary Care of People with HIV/AIDS - Canadian Public ...
A Guide to Primary Care of People with HIV/AIDS - Canadian Public ...
A Guide to Primary Care of People with HIV/AIDS - Canadian Public ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
A <strong>Guide</strong> <strong>to</strong> <strong>Primary</strong> <strong>Care</strong> <strong>of</strong> <strong>People</strong> <strong>with</strong> <strong>HIV</strong>/<strong>AIDS</strong><br />
Chapter 12: Family Planning and Pregnancy<br />
• Testing should be performed as early as possible<br />
in pregnancy <strong>to</strong> allow for timely interventions and<br />
decisions.<br />
• <strong>HIV</strong>-negative women who are at high risk <strong>of</strong> acquiring<br />
<strong>HIV</strong> should be retested in the third trimester <strong>of</strong><br />
pregnancy (ideally before 36 weeks). Women are at<br />
high risk if they have a his<strong>to</strong>ry <strong>of</strong> STDs, exchange sex<br />
for money or drugs, have multiple sex partners during<br />
pregnancy, use illicit drugs, have <strong>HIV</strong>-positive or highrisk<br />
sex partners, and/or show signs and symp<strong>to</strong>ms <strong>of</strong><br />
seroconversion.<br />
• Women whose <strong>HIV</strong> status is unknown and/or who<br />
present late in pregnancy or already in labor should<br />
be assessed promptly for <strong>HIV</strong> infection, using rapid<br />
<strong>HIV</strong> testing, <strong>to</strong> allow for timely prophylactic treatment.<br />
Standard confirma<strong>to</strong>ry tests should be done after<br />
delivery for women <strong>with</strong> positive rapid test results.<br />
• CDC recommends timely, routine screening <strong>of</strong> an<br />
infant if the mother has not been tested during<br />
pregnancy or delivery (CDC, 2003).<br />
How should <strong>HIV</strong> testing be done?<br />
<strong>HIV</strong> testing should be voluntary, and providers should<br />
carefully document informed consent. Providers<br />
should <strong>of</strong>fer pre- and post-test counseling that includes<br />
information on modes <strong>of</strong> transmission <strong>of</strong> the virus, risk<br />
fac<strong>to</strong>rs that might be present even if a woman has only<br />
one sex partner, and effective interventions <strong>to</strong> reduce<br />
the risk <strong>of</strong> perinatal transmission <strong>of</strong> <strong>HIV</strong>. There should<br />
be a discussion <strong>of</strong> services available for the provision<br />
<strong>of</strong> medical care, and the woman should be reassured<br />
that care for her and her infant will not be denied if she<br />
declines the test. Laws and regulations on <strong>HIV</strong> screening<br />
<strong>of</strong> pregnant women and their infants vary by State.<br />
Therefore, providers should be familiar <strong>with</strong> the State<br />
regulations and policies that apply <strong>to</strong> them (CDC, 2001).<br />
When does transmission from mother <strong>to</strong><br />
infant occur and what are risk fac<strong>to</strong>rs for<br />
transmission?<br />
Vertical transmission can occur during the perinatal<br />
period and infancy, that is, before or close <strong>to</strong> the time<br />
<strong>of</strong> birth or during breastfeeding. Risk fac<strong>to</strong>rs associated<br />
<strong>with</strong> vertical transmission include (CDC, 2001):<br />
• Advanced disease in the mother<br />
• High plasma viral load<br />
• Maternal injection drug use during pregnancy<br />
• Preterm delivery<br />
• HCV coinfection<br />
• Failure <strong>to</strong> follow the recommended regimen <strong>of</strong><br />
zidovudine prophylaxis<br />
• Breast-feeding<br />
• Delivery more than 4 hours after rupture <strong>of</strong><br />
membranes<br />
• Concurrent STDs<br />
• Chorioamnionitis<br />
• Certain obstetrical procedures<br />
How common is vertical transmission <strong>of</strong> <strong>HIV</strong><br />
<strong>with</strong> and <strong>with</strong>out ART?<br />
In the absence <strong>of</strong> antiretrovirals, the perinatal<br />
transmission rate <strong>of</strong> <strong>HIV</strong> infection is approximately<br />
25%. There is a direct correlation between maternal<br />
viral load as measured by plasma <strong>HIV</strong>-1 RNA and<br />
probability <strong>of</strong> perinatal transmission. A large study<br />
showed that the rate <strong>of</strong> perinatal transmission among<br />
women <strong>with</strong> viral load >100,000 c/mL was 40.6%,<br />
<strong>with</strong> 50,001 <strong>to</strong> 100,000 c/mL it was 30.9%, <strong>with</strong> 10,001<br />
<strong>to</strong> 50,000 c/mL it was 21.3%, <strong>with</strong> 1,000 <strong>to</strong> 10,000<br />
c/mL it was 16.6%; and <strong>with</strong>